Prescription drug · ANDA
Fenofibrate NDC 73352-101
Fenofibrate 40 mg/1 · Tablet · Oral · Trifluent Pharma LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 73352-101-01 | 73352010101 | 90 TABLET in 1 BOTTLE (73352-101-01)Marketed from Aug 12, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Fenofibrate
- Generic name (nonproprietary)
- fenofibrate
- Active ingredients
- Fenofibrate — 40 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Trifluent Pharma LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 217732
- Marketing start
- Listing expires
- Identifiers
- Product ID 73352-101_3c3539f7-7a1e-8fd3-e063-6294a90a1082SPL ID 3c3539f7-7a1e-8fd3-e063-6294a90a1082SPL set ID 3c3539e4-bc4a-8152-e063-6294a90ab55cRxCUI 749802, 749804UNII U202363UOSUPC 0373352101016, 0373352102013
- Pharmacologic class
- Peroxisome Proliferator Receptor alpha Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N473352010101followed by a unit qualifier and the quantityPackage 73352-0101-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Fenofibrate tablets are indicated as adjunctive therapy to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. Limitations of Use Markedly elevated levels of serum TG (e.g., >2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined [see Warnings and Precautions (5.7) ]. Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized contro…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 217732
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Fenofibrate | Fenofibrate 40 mg/1 | TabletOral | Bryant Ranch Prepack | 71335-2628 |
| Fenofibrate | Fenofibrate 120 mg/1 | TabletOral | Bryant Ranch Prepack | 71335-2629 |
| Fenofibrate | Fenofibrate 120 mg/1 | TabletOral | Bryant Ranch Prepack | 72162-2470 |
| Fenofibrate | Fenofibrate 40 mg/1 | TabletOral | Bryant Ranch Prepack | 72162-2469 |
| Fenofibrate | Fenofibrate 120 mg/1 | TabletOral | Trifluent Pharma LLC | 73352-102 |
| Fenofibrate | Fenofibrate 40 mg/1 | TabletOral | Creekwood Pharmaceuticals LLC | 82619-101 |
| Fenofibrate | Fenofibrate 120 mg/1 | TabletOral | Creekwood Pharmaceuticals LLC | 82619-102 |